A complete UI kit

Stay up to date

Customers love it

Publications

View Case Studies
back to overview
Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
Steuber T, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Golding B, Schiess R, Gillessen S. BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540. PMID: 30216634
Thrombospondin 1 and cathepsin D improve the detection of high-grade prostate cancer and reduce the number of unnecessary prostate biopsies
Klocker H, Steiner E, Horninger W, Thomas S, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Schiess R, Gillessen S. 33rd Annual EAU Congress, 16-20 March 2018, Copenhagen, Denmark
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
Endt K, Goepfert J, Omlin A, Athanasiou A, Tennstedt P, Guenther A, Rainisio M, Engeler DS, Steuber T, Gillessen S, Joos T, Schiess R. PLoS One. 2017 Aug 2;12(8):e0181557. PMID: 28767721
A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: findings of a recent study
Tennstedt P, Steuber T, Macagno A, Golding B, Schiess R, Gillessen S. 112th AUA Annual Meeting, 12-16 May 2017, Boston, United States
A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: findings of a recent study
Steuber T, Tennstedt P, Macagno A, Golding B, Schiess R, Gillessen S. 32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom
Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Eur Urol. 2014 Jan 4. [Epub ahead of print] PMID: 24412228
Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Eur Urol. 2013 Jul;64(1):150-8. Epub 2013 Apr 6. PMID: 23582881
N-Glycoprotein SRMAtlas: A RESOURCE OF MASS SPECTROMETRIC ASSAYS FOR N-GLYCOSITES ENABLING CONSISTENT AND MULTIPLEXED PROTEIN QUANTIFICATION FOR CLINICAL APPLICATIONS.
Hüttenhain R, Surinova S, Ossola R, Sun Z, Campbell D, Cerciello F, Schiess R, Bausch-Fluck D, Rosenberger G, Chen J, Rinner O, Kusebauch U, Hajdúch M, Moritz RL, Wollscheid B, Aebersold R. Mol Cell Proteomics. 2013 Apr;12(4):1005-16. Epub 2013 Feb 13. PMID: 23408683
Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; for the Swiss Group for Clinical Cancer Research (SAKK). Clin Cancer Res. 2012 Nov 1;18(21):6049-57. Epub 2012 Sep 12. PMID: 22977195
Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome.
Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T, Aebersold R, Krek W, Gillessen S. Eur Urol. 2011 Dec;60(6):1235-43. Epub 2011 Jun 29. PMID: 21741162
Cancer genetics-driven discovery of serum biomarker signatures for diagnosis and prognosis of human prostate cancer.
Cima I, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Proc Natl Acad Sci U S A. 2011 Feb 7. [Epub ahead of print] PMID: 21300890
On the Development of Plasma Protein Biomarkers.
Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R. J Proteome Res. 2011 Jan 7;10(1):5-16. Epub 2010 Dec 13. PMID: 21142170
Biomarker Validation in Blood Specimens by Selected Reaction Monitoring Mass Spectrometry of N-Glycosites.
Ossola R, Schiess R, Picotti P, Rinner O, Reiter L, Aebersold R. Methods Mol Biol. 2011;728:179-194. PMID: 21468948
Targeted Proteomic Strategy for Clinical Biomarker Discovery.
Schiess R, Wollscheid B, Aebersold R. Mol Oncol. 2009 Feb;3(1):33-44. Epub 2008 Dec 11. Review. PMID: 19383365
Cancer genetics-driven discovery of serum biomarker signatures for diagnosis and prognosis of human prostate cancer.
Cima I, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Proc Natl Acad Sci U S A. 2011 Feb 7. [Epub ahead of print] PMID: 21300890